{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:56:14Z","timestamp":1762005374509,"version":"build-2065373602"},"reference-count":18,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T00:00:00Z","timestamp":1652227200000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Brazilian Journal of Infectious Diseases"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.bjid.2022.102369","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T08:01:02Z","timestamp":1653292862000},"page":"102369","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["In vitro activity of ceftazidime-avibactam against Gram-negative strains in patients with complicated urinary tract infection and complicated intra-abdominal infection in Colombia 2014-2018"],"prefix":"10.1016","volume":"26","author":[{"given":"Elkin V.","family":"Lemos-Luengas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sixta","family":"Renter\u00eda-Valoyes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1030-8418","authenticated-orcid":false,"given":"Paola","family":"C\u00e1rdenas-Isaza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3297-0012","authenticated-orcid":false,"given":"Jorge A.","family":"Ramos-Castaneda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bjid.2022.102369_bib0001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4067\/S0716-10182017000100001","article-title":"Factores asociados a nefrotoxicidad por polimixina B en un hospital universitario de Neiva, Colombia. 2011-2015","volume":"34","author":"Osorio","year":"2017","journal-title":"Rev Chilena Infect"},{"key":"10.1016\/j.bjid.2022.102369_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106439","article-title":"Activity of Ceftazidime-Avibactam, Meropenem-Vaborbactam, and Imipenem-Relebactam against Carbapenemase-negative Carbapenem-resistant Enterobacterales (CRE) isolates from US Hospitals","author":"Castanheira","year":"2021","journal-title":"Inter J Antimicrob Agen"},{"key":"10.1016\/j.bjid.2022.102369_bib0003","first-page":"1","article-title":"The ERACE-PA global surveillance program: Ceftolozane\/tazobactam and Ceftazidime\/avibactam in vitro activity against a global collection of Carbapenem-resistant Pseudomonas aeruginosa","author":"Gill","year":"2021","journal-title":"Euro J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.bjid.2022.102369_bib0004","first-page":"1396","article-title":"In vitro activity of ceftazidime\/avibactam against urinary isolates from patients in a Phase 3 clinical trial programme for the treatment of complicated urinary tract infections","volume":"72","author":"Stone","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bjid.2022.102369_bib0005","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01820-16","article-title":"In Vitro activity of ceftazidime-avibactam against isolates in a phase 3 open-label clinical trial for complicated intra-abdominal and urinary tract infections caused by ceftazidime-nonsusceptible gram-negative pathogens","volume":"61","author":"Stone","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2022.102369_bib0006","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.ijantimicag.2018.01.011","article-title":"Activity of ceftazidime-avibactam against carbapenemase-producing Enterobacteriaceae from urine specimens obtained during the infection-carbapenem resistance evaluation surveillance trial (iCREST) in Spain","volume":"51","author":"Garc\u00eda-Castillo","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.bjid.2022.102369_bib0007","unstructured":"Ministerio de Salud y Protecci\u00f3n Social, Instituto Nacional de Vigilancia de Medicamentos y Alimentos \u2013 INVIMA. Resoluci\u00f3n No. 2019052727 de Noviembre 22 de 2019 [Internet]. 2019. Available from:https:\/\/www.invima.gov.co\/documents\/20143\/1587207\/INVIMA+2019M+19450-2019052727.pdf"},{"key":"10.1016\/j.bjid.2022.102369_bib0008","unstructured":"Pfizer. ATLAS (Antimicrobial Testing Leadership And Surveillance) [Internet]. Available from:https:\/\/atlas-surveillance.com\/\/#\/login"},{"key":"10.1016\/j.bjid.2022.102369_bib0009","unstructured":"Scientific S, Unit HB. ATLAS\u00a0: Fully - searchable global antibiotic resistance database to fight AMR Testing ATLAS\u00a0: antimicrobial and surveillance history of Pfizer-sponsored surveillance progra ms. 2019."},{"key":"10.1016\/j.bjid.2022.102369_bib0010","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jgar.2022.02.018","article-title":"In vitro activity of ceftazidime\/avibactam against Gram-negative strains in Colombia 2014\u20132018","volume":"29","author":"Lemos-Luengas","year":"2022","journal-title":"J Global Antim Resist"},{"issue":"2","key":"10.1016\/j.bjid.2022.102369_bib0011","article-title":"Clinical experience with ceftazidime-avibactam for the treatment of infections due to multidrug-resistant gram-negative bacteria other than carbapenem-resistant enterobacterales","volume":"9","author":"Vena","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.bjid.2022.102369_bib0012","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/INF.0000000000002392","article-title":"Safety and efficacy of ceftazidime-avibactam plus metronidazole in the treatment of children\u2265 3 months to < 18 years with complicated intra-abdominal infection: results from a phase 2, randomized, controlled trial","volume":"38","author":"Bradley","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.bjid.2022.102369_bib0013","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/INF.0000000000002395","article-title":"Safety and efficacy of Ceftazidime\u2013Avibactam in the treatment of children\u2265 3 months to < 18 years with complicated urinary tract infection: results from a phase 2 randomized, controlled trial","volume":"38","author":"Bradley","year":"2019","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"10.1016\/j.bjid.2022.102369_bib0014","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.ijantimicag.2019.06.008","article-title":"Cost-effectiveness analysis of ceftazidime\/avibactam compared to imipenem as empirical treatment for complicated urinary tract infections","volume":"54","author":"Kongnakorn","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.bjid.2022.102369_bib0015","first-page":"1","article-title":"Cost-utility analysis of ceftazidime-avibactam versus colistin-meropenem in the treatment of infections due to Carbapenem-resistant Klebsiella pneumoniae in Colombia","volume":"0","author":"Var\u00f3n-Vega","year":"2021","journal-title":"Expert Rev Pharmacoeconomics Outcomes Res"},{"key":"10.1016\/j.bjid.2022.102369_bib0016","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2174\/1573396312666161205102221","article-title":"Management of pneumonia in the pediatric critical care unit: an area for antimicrobial stewardship","volume":"1","author":"Dassner","year":"2017","journal-title":"Curr Pediatr Rev"},{"key":"10.1016\/j.bjid.2022.102369_bib0017","unstructured":"Bravo Ojeda JS. Descripci\u00f3n de tipos de carbapenemasas expresadas en Klebsiella sp. y Pseudomonas aeruginosa en hospitales de tercer nivel de la ciudad de Bogot\u00e1, estudio descriptivo. Parte 3: Comportamiento microbiol\u00f3gico y los mecanismos gen\u00e9ticos en aislamientos de Pseudomonas aeruginosa portadores del gen blaKPC en hospitales de tercer nivel de Bogot\u00e1. 2020 Jul 1 [cited 2021 Nov 19]; Available from: https:\/\/repositorio.unal.edu.co\/handle\/unal\/77807"},{"year":"2020","series-title":"M100 Performance Standards for Antimicrobial Susceptibility Testing","key":"10.1016\/j.bjid.2022.102369_bib0018"}],"container-title":["The Brazilian Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1413867022000575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1413867022000575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T15:57:54Z","timestamp":1761407874000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1413867022000575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S1413867022000575"],"URL":"https:\/\/doi.org\/10.1016\/j.bjid.2022.102369","relation":{},"ISSN":["1413-8670"],"issn-type":[{"type":"print","value":"1413-8670"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of ceftazidime-avibactam against Gram-negative strains in patients with complicated urinary tract infection and complicated intra-abdominal infection in Colombia 2014-2018","name":"articletitle","label":"Article Title"},{"value":"The Brazilian Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bjid.2022.102369","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Sociedade Brasileira de Infectologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"102369"}}